Sign inCreate account

Report workspace tools

NCT01055314COMPLETEDanonymous

A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma

Sponsor

Source record

National Cancer Institute (NCI)

Phase

Source record

Phase 2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Metastatic Rhabdomyosarcoma

Indication / condition

AI-normalized

Adult Rhabdomyosarcoma

Intervention

Source record

Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome

Source & freshness

Source record

NCT ID

NCT01055314

Original source

ClinicalTrials.gov

Source last updated

Aug 29, 2017

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01055314

Title

A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma

Sponsor

National Cancer Institute (NCI)

Status

COMPLETED

Phase

Phase 2

Condition raw

Adult Rhabdomyosarcoma

Condition normalized

Adult Rhabdomyosarcoma

Modality raw

Adult Rhabdomyosarcoma

Modality normalized

monoclonal antibody

Target raw

Metastatic Rhabdomyosarcoma

Target normalized

Metastatic Rhabdomyosarcoma

Interventions

Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome

Public preview

Source record

This pilot study evaluated the feasibility and efficacy of combining temozolomide and cixutumumab with a multi-agent chemotherapy regimen for high-risk metastatic rhabdomyosarcoma in children and adults. The study was sponsored by the National Cancer Institute and involved 175 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01055314

Status

COMPLETED

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Executive brief

Investment-Ready Snapshot

This pilot study evaluated the feasibility and efficacy of combining temozolomide and cixutumumab with a multi-agent chemotherapy regimen for high-risk metastatic rhabdomyosarcoma in children and adults. The study was sponsored by the National Cancer Institute and involved 175 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 29, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01055314

Indication

Adult Rhabdomyosarcoma

Modality

monoclonal antibody

Target

Metastatic Rhabdomyosarcoma

Intervention

Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.